Compare CERS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | BNR |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 233.7M |
| IPO Year | 1997 | 2020 |
| Metric | CERS | BNR |
|---|---|---|
| Price | $2.03 | $15.94 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 68.7K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,191,000.00 | $75,749,382.00 |
| Revenue This Year | $25.31 | $136.32 |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.03 | 5.56 |
| 52 Week Low | $1.12 | $2.18 |
| 52 Week High | $2.25 | $23.59 |
| Indicator | CERS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 48.32 |
| Support Level | $1.83 | $15.71 |
| Resistance Level | $2.25 | $18.42 |
| Average True Range (ATR) | 0.14 | 2.38 |
| MACD | 0.02 | -0.71 |
| Stochastic Oscillator | 65.52 | 2.26 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.